NCT06576037 2025-10-15
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
8 trialsNCT04937153 2025-07-16
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
Genmab
Phase 1 Completed
NCT02608385 2025-06-08
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
University of Chicago
Phase 1 Active not recruiting
NCT05176509 2025-01-06
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT03588039 2023-05-19
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Athenex, Inc.
Phase 1 Terminated
NCT03894540 2022-09-13
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Ipsen
Phase 1 Terminated
NCT04866485 2021-04-29
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 1 Unknown
NCT02987166 2020-12-16
UVA-AM-001
University of Virginia
Phase 1 Completed